GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evoke Pharma Inc (STU:EV00) » Definitions » Institutional Ownership

Evoke Pharma (STU:EV00) Institutional Ownership : 0.42% (As of May. 16, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Evoke Pharma Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Evoke Pharma's institutional ownership is 0.42%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Evoke Pharma's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Evoke Pharma's Float Percentage Of Total Shares Outstanding is 99.00%.


Evoke Pharma Institutional Ownership Historical Data

The historical data trend for Evoke Pharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evoke Pharma Institutional Ownership Chart

Evoke Pharma Historical Data

The historical data trend for Evoke Pharma can be seen below:

2023-05-31 2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 0.90 0.88 0.88 0.88 1.06 1.06 1.06 1.06 0.42 0.42

Evoke Pharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Evoke Pharma (STU:EV00) Business Description

Traded in Other Exchanges
Address
420 Stevens Avenue, Suite 370, Solana Beach, CA, USA, 92075
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.

Evoke Pharma (STU:EV00) Headlines

No Headlines